AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04130438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diltiazem
Description: The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.
Study NCT01170312 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline injection
Study NCT04130438 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The intervention to be tested is oral beta blocker (nebivolol 2.5 mg) vs. calcium channel blocker (Diltiazem-SR 120 mg) vs. placebo. Once enrolled, baseline data will be gathered and subjects will be randomly assigned to a treatment arm. Subjects will be instructed to take their assigned study drug once a day for 30 days.
Study NCT04048629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) viral load (VL) testing plus refresher training
Description: VL testing at the first antenatal care visit will occur using POC VL testing in pregnant women, and a refresher training on Zimbabwe's guidelines will be provided at all facilities
Study NCT04048629 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care central laboratory VL testing plus refresher training
Description: VL testing at the first antenatal care visit will occur using central laboratory VL testing in pregnant women, and a refresher training on Zimbabwe's guidelines will be provided at all facilities
Study NCT03228706 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Know Your Medicine - Take It For Health (KYM-TIFH)
Description: The KYM-TIFH employed psychosocial, educational and behavioral approach. It was designed based on the application of multiple behavior change theories and persuasion theory as recommended by Slater (1999). The cross-theoretical framework for the message design of intervention as recommended by Slater (1999) involved theories such as Transtheoretical Model (TTM) (Prochaska \& Velicer 1997), Theory of Reasoned Action (TRA) (Ajzen \& Fishbein 1980), Protection Motivation Theory (PMT) (Rogers 1975), Elaboration-Likelihood Model (ELM) (Petty and Cacioppo 1986) and Social Cognitive Theory (SCT) (Bandura 1992) as in Table 2. Nonetheless, the intervention embraces the philosophy of patients' empowerment, which had found to be effective in engaging patients to produce behavioral change among diabetes patients (Anderson 1995; Anderson et al 1995). Hence, the facilitators are trained to employ a non-didactic approach in facilitating the and eliciting the learning among the group members.
Study NCT03989856 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2-0 polyglican absorbable sutures
Description: The sutures will be performed with intracorporeal knots using 2-0 polyglican absorbable sutures (Vicryl; Ethicon Inc., New Jersey, USA). Suture is performed using needle holders for the closure of ovarian parenchyma and controlling bleeding. Bleeding from ovarian hilus will only resolve by suturing.
Study NCT03989856 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diathermy
Description: bipolar coagulation technique will be used to control significant bleeding (40 W current; Richard Wolf, Germany). I
Study NCT03175562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial micellar cleanser
Description: Participant will have each product applied topically via semi occlusive patch, on site by the technician. Each patch will remain in place for 48 (± 2) hours on weekdays and 72 (± 2) hours on weekends.
Study NCT03175562 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Saline Solution: Sodium Chloride (NaCl; 0.9%)
Description: Participant will have each product applied topically via semi occlusive patch, on site by the technician. Each patch will remain in place for 48 (± 2) hours on weekdays and 72 (± 2) hours on weekends.
Study NCT00844324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Description: Formulation:Oral suspensionStrength:1 mg/mLDose: 32 mg, single dose
Study NCT00844324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Description: Formulation:Oral suspensionStrength:1.6 mg/mLDose: 32 mg, single dose
Study NCT02109068 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss Counseling- Phone
Description: The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.~During the 6-month intervention, participants will receive weekly (month 1), then bi-weekly (months 2 and 3), then monthly (months 4, 5, and 6) individualized counseling sessions. An advantage of tapering the frequency of visits from weekly to every other week and then monthly works as a process tool to help transfer the work or responsibility onto the participant for life long change and maintenance of behavior change.
Study NCT02109068 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss Counseling- In-Person
Description: The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.~During the 6-month intervention, participants will receive weekly (month 1), then bi-weekly (months 2 and 3), then monthly (months 4, 5, and 6) individualized counseling sessions. An advantage of tapering the frequency of visits from weekly to every other week and then monthly works as a process tool to help transfer the work or responsibility onto the participant for life long change and maintenance of behavior change.
Study NCT02540512 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Auricular Acupuncture
Description: Aiguille Semi-Permanent (ASP) acupuncture needles will be used following the Battlefield Acupuncture Protocol
Study NCT02540512 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: ASP Needles: Small, semi-permanent acupuncture needles that will be used for acupuncture in the ear or taped over the ear for placebo.
Study NCT02540512 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Acupuncture
Description: ASP Needles: Small, semi-permanent acupuncture needles that will be used for acupuncture in the ear or taped over the ear for placebo.
Study NCT02540512 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Acupuncture
Description: The ASP needles will be double taped onto the ear for this procedure.
Study NCT02540512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hydrocodone / acetaminophen 5mg/325mg
Description: Narcotic/NSAID medication used as the standard medical treatment
Study NCT02540512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocodone / acetaminophen 5mg/325mg
Description: Narcotic/NSAID medication used as the standard medical treatment
Study NCT02540512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Pill
Description: Pills will be filled with methylcellulose and administered as a placebo for this intervention.
Study NCT04965792 — intervention group
Intervention type: OTHER
Intervention: Screening
Description: Blood test
Study NCT03741907 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FAUCS
Description: extraperitoneal cesarean with a paramedian left section
Study NCT03741907 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MLC
Description: Gold standard
Study NCT02097628 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tidal volume
Description: In the volume controlled ventilation group using laryngeal mask airway Guardian,a tidal volume of 8-12ml/kg,respiratory rate12-16bpm.
Study NCT02097628 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peak airway pressure
Description: In the pressure controlled ventilation group using laryngeal mask airway Guardian,a peak airway pressure that provides a tidal volume of 8-12ml/kg with an upper limit of 35 centimeter water column,respiratory rate12-16bpm.
Study NCT01119196 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Icodextrin dialysate
Description: use of alternate SOC dialysate
Study NCT00886860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol
Description: misoprostol 50 micrograms oral every 4 hours until cervical dilatation 3 cm
Study NCT00886860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol
Description: misoprostol 20 micrograms oral every hours until cervical dilatation 3 cm
Study NCT01746381 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive home ventilation
Description: A ventilator and mask will be provided to patients according to standard procedures used at the National Program of Home Ventilatory Assistance of the Montreal Chest Institute, adjusted during a daytime outpatient trial, with close follow-up as described in study protocol.
Study NCT01746381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive home ventilation
Description: A ventilator and mask will be provided to patients according to standard procedures used at the National Program of Home Ventilatory Assistance of the Montreal Chest Institute, adjusted during a daytime outpatient trial, with close follow-up as described in study protocol.
Study NCT03754556 — intervention group
Intervention type: DEVICE
Intervention: Intrauterine device
Description: Intrauterine devices, e.g. BAY86-5028 (Mirena, Skyla, Kyleena), Liletta and ParaGard
Study NCT01174979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caroverin
Description: treatment with eardrops 2 times for 48 hours
Study NCT01174979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Caroverin
Description: treatment with eardrops 2 times for 48 hours
Study NCT01413711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vigabatrin
Description: Oral vigabatrin as a single 25 mg/kg dose on Days 1 and 5, 25 mg/kg twice a day (50 mg/kg daily dose, orally) on Days 2-4
Study NCT03238703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Given PO
Study NCT03238703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Given PO
Study NCT03238703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03238703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Given PO
Study NCT03238703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03238703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03238703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Citrate
Description: Given PO
Study NCT03238703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toremifene Citrate
Description: Given PO
Study NCT01440114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: In intervention group patient received fentanyl 1 mcg/kg intravenous 15 minutes before the end of surgery.
Study NCT01440114 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NSS
Description: Patient in this group received NSS (0.1ml/kg)intravenous route 15 minutes before the end of surgery.
Study NCT00770562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT00770562 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study NCT00770562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study NCT04444271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: 1. Frozen MSCs will be resuspended in 100ml normal saline for immediate use and given intravenously. The patients should be pre-medicated to avoid allergic reactions to third party MSCs. Each patient in Experimental arm will be given 2 x 106 cells/kg will be administered on day 1,7 in addition to supportive care
Study NCT04444271 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 ml of normal saline will be given intravenously to control arm
Study NCT00587808 — intervention group
Intervention type: PROCEDURE
Intervention: RHC with VO2 consumption
Description: All pressure-volume data is acquired at 250 Hz and stored on the Leycom system for offline analysis. Volume data will be calibrated using the most recent EF from echocardiogram and stroke volume from the Fick method. Measured O2 consumption will be utilized along with sampling of SVC and arterial blood oximetry to determine cardiac output at rest and during exercise
Study NCT02229825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Capsule
Study NCT02229825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsule
Study NCT03797963 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PBM+ACB
Description: Maxillary sinus floor elevation and bone grafting with the use of porcine bone mineral biomaterial (Symbios Xenograft) combined with autogenous cortical bone
Study NCT03797963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ABB+ACB
Description: Maxillary sinus floor elevation and bone grafting with the use of anorganic bovine bone biomaterial (BioOss Xenograft) combined with autogenous cortical bone
Study NCT03634098 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: new quantitative imaging techniques with contast products
Description: magnetic resonance +/- Primovist and ultrafast ultrasound UFUS +Sonovue
Study NCT03634098 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood sample
Description: extensive clinical-biological phenotyping data; and / or data obtained by different omic approaches (metabolomics, targeted genetics, transcriptomics). Extracellular vesicle and immune cell profiling will complement this data
Study NCT03634098 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: second generation tests
Description: second generation tests NIT-NASHr et NIT-A2F2
Study NCT01500785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levosimendan
Description: infusion; levosimendan (12 μg/kg) The study drug will be administered together with the induction of cardioplegia solution during five minutes (=once for each patient)
Study NCT01500785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin B 12
Description: Infusion made of Glucos B.Braun 50 mg/ml infusion together with vitamin B12 which is used to colour the glucose infusion to look identical to Simdax infusion The placebo will be administered together with the induction of cardioplegia solution during five minutes (=once for each patient).
Study NCT00292045 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 protein/CpG 7909
Description: Patients received vaccinations consisting of the NY-ESO-1 protein (100 µg) combined with CpG 7909 (2.5 mg) as an adjuvant administered intradermally every 3 weeks for 4 doses (i.e., 12-week cycle).
Study NCT04281420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-019
Description: ATG-019 30 mg QoD×3 is selected as the staring dose. Oral ATG-019 will be taken three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28-day cycle.
Study NCT04281420 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ATG-019 + Niacin ER
Description: ATG-019 60 mg is selected as starting dose. Oral ATG-019 will be taken three times a week every other day (Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26) during each 28-day cycle. And a starting dose of 500 mg niacin ER (may be titrated up to 1,000 mg of daily dose, per label) co-administered with each dose of ATG-019.
Study NCT03623386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PD neurofeedback
Description: PD-neurofeedback subjects will practice motor imagery in the MRI scanner and receive neurofeedback on their performance. There will be a total of 10-12 neurofeedback sessions on two separate days. Subjects will continue practicing motor imagery at home every day throughout the study period for 4-6 weeks.
Study NCT03623386 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PD control
Description: PD-control subjects will practice visual imagery (e.g., of scenery, objects, etc., but not of movement) in the MRI scanner and will not receive neurofeedback on their performance. Subjects will continue practicing visual imagery at home every day throughout the study period for 4-6 weeks.
Study NCT03188666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2477
Description: Pharmaceutical form: liquid product for injection/infusion; Route of administration: Intravenous (IV); Administered during treatment periods 1 and 2.
Study NCT03188666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Pharmaceutical form: Liquid product for injection/infusion; Route of administration: Intravenous (IV); Administered during treatment period 1 only.
Study NCT03008876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: infants receive acetaminophen for treatment of their PDA
Study NCT03008876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: infants receive ibuprofen, standard of care in our unit, for treatment of a PDA
Study NCT02903719 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ropivacaine
Description: All included patients with a right sided shoulder pain score on a numeric rating scale (NRS) equal to or above 6 and without postoperative exclusion criteria will have two (1st and 2nd intervention) ultrasound guided phrenic nerve blocks performed.
Study NCT04120090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low dose ruxolitinib
Description: The dose for adult patients(Age>=14 years) is generally 10 mg twice daily. For children(Age\<14 years ,weight >=25kg),the dose was generally 5mg twice daily. For children(Age\<14 years, weight \<25kg), the dose was generally 2.5mg twice daily.
Study NCT03462641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flumazenil
Description: 1mg in 10cc normal saline
Study NCT03462641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 10 cc normal saline
Study NCT04120090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose ruxolitinib
Description: The dose for adult patients(Age>=14 years) is generally 20mg twice daily. For children(Age\<14 years ,weight >=25kg),the dose was generally 10mg twice daily. For children(Age\<14 years, weight \<25kg), the dose was generally 5mg twice daily
Study NCT04060043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: The Pepti 10.8mg (goserelin acetate) implant is supplied as a cylindrical rod of biodegradable and biocompatible D, L Lactic and glycolic acids copolymer. Each implant contains goserelin acetate equivalent to 10.8mg of goserelin as well as a blend of high and low molecular weight range of D, L lactic and glycolic acids copolymer to total a weight of approximately 36.0mg per depot. The implant will be injected subcutaneously through the patient's anterior abdominal wall.
Study NCT06137690 — intervention group
Intervention type: DEVICE
Intervention: other antifungal agents,breathing machine
Description: If treatment failure for patients in group A and group B，change other antifungal agents (Amphotericin B for Injection, 25mg, North China Pharmaceutical Co., Ltd or Caspofungin Acetate for lnjection,50mg and 70mg Cancidas®). Mechanical ventilation (EVITA 4, Dräger Medical Equipment (Shanghai) Co.,Ltd) was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of antifungal agents therapy.
Study NCT03837743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DUR-928 Topical Solution
Description: Topical solution containing active drug
Study NCT03837743 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Topical Solution
Description: Topical solution containing no active drug
Study NCT03956810 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: On-demand transportation
Description: On-demand scheduling via telephone, web portal, or the broker's mobile application.
Study NCT03956810 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual transportation
Description: Usual transportation scheduling via call-center.
Study NCT02302547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triple therapy
Description: Dosage treatment and usual prescription
Study NCT02302547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dual therapy
Description: 1 tablet (200mg/245mg) daily for 48 weeks
Study NCT00106340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin
Study NCT03974126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 40 grams of starch
Description: 40 grams of starch in form of white bread to be consumed within 15 minutes